Furosemide

Mechanism

Pharmacological Class and Group

High potency sulfamide diuretic belonging to the class of Loop Diuretics (Sodium-Potassium-2-Chlorine Co-transporter Inhibitors).

Mechanism of Action

The ascending loop of Henle actively reabsorbs approximately 25% of the filtered sodium load of the nephron. This concentrating function depends exclusively on the apical electroneutral co-transporter Na⁺/K⁺/2Cl^- type 2 (NKCC2) massively expressed in the thick ascending segment.

Molecular Mechanism of Action in the Loop of Henle

1. Active excretion into the tubular lumen: Furosemide is highly bound to plasma albumin, which prevents its direct glomerular filtration. It enters the lumen of the nephron actively through organic anion transporters (OAT1 and OAT3) located in the basolateral membrane of the proximal convoluted tubule cells.

2. Reversible inhibition of the NKCC2 transporter: Once in the lumen of the renal tubule, furosemide travels with the urinary flow to the thick ascending portion of the loop of Henle, where it competitively binds to the chloride active site on the apical co-transporter NKCC2, completely abolishing its ionic translocation capacity:

Furosemide NKCC2 ↓ Coordinated reabsorption of Na⁺, K⁺ and Cl^-

3. Loss of positive potential difference and cation excretion: Inhibition of NKCC2 disrupts continuous apical recycling of potassium through the ROMK channel. This abrogates the usual positive transepithelial electrical potential of +10 mV in the tubule lumen, eliminating the driving force for paracellular passive reabsorption of divalent cations:

Annulation of the transepithelial potential ↑ Massive renal excretion of Ca²⁺ and Mg²⁺

4. Induction of Osmotic Diuresis: As these electrolytes are not reabsorbed, the hypertonic medullary osmotic gradient is altered, which prevents the passive reabsorption of water in the collecting duct and generates a rapid and massive excretion of free water and sodium.

Pharmacokinetics

High Resolution Pharmacokinetics

• Absorption and Bioavailability: Highly variable oral bioavailability (ranging from 10% to 90%, average 50%). The edema of the intestinal wall present in decompensated heart failure substantially delays the absorption of the drug, prolonging the onset of its action.
• Distribution: High binding to plasma albumin (95% - 98%). It does not significantly penetrate peripheral soft tissues due to its high ionic charge.
• Metabolism: Marginal hepatic metabolism (approximately 10%) by conjugation to a glucuronide derivative.
• Excretion: Exclusive renal excretion by active proximal tubular secretion (65% unchanged, 15% as glucuronide).
• Half-life (t_1/2) and Onset: By intravenous route, the diuretic effect begins after 5 minutes and reaches its peak in 30 minutes, with a duration of 2 hours. Orally, the effect begins after 30-60 minutes with an average duration of 6 to 8 hours (hence the classic Latin expression Lasix = LAst SIX hours).

Indicators and dose

Clinical Indications and Uses

• Congestive Heart Failure (Acute Decompensation Episodes): First-line intravenous treatment to immediately correct pulmonary congestion and generalized systemic edema.
• Edema of Renal or Hepatic Origin (Nephrotic Syndrome / Ascites): For the management of interstitial tissue volume overload.
• Chronic Renal Failure with volume retention: Maintains diuretic efficacy even in advanced stages of glomerular filtration loss (unlike thiazides).
• Emergency Hypercalcemia: Administered together with physiological solution to promote rapid renal excretion of calcium.

Dosage and Clinical Adjustment

• Chronic Volume Overload (Outpatient Management): 20 mg to 80 mg per day orally, administered preferably in the morning so as not to interfere with the patient's sleep cycle.
• Acute Lung Edema: Intravenous bolus of 20 mg to 40 mg initially (or a dose equivalent to the patient's daily oral maintenance dose). It can be repeated after 1-2 hours or escalated according to the clinical response of hourly diuresis.
• Adjustment in Renal Failure: In patients with advanced failure (eGFR < 30 mL/min/1.73 m²), the amount of drug that reaches the tubule by filtration decreases drastically. Significantly higher starting doses (80 mg to 120 mg orally or intravenously) are required to achieve the local effective diuresis threshold.

Security

Absolute and Relative Contraindications

Absolute Contraindications

• Established obstructive anuria refractory to maximum doses of diuretics.
• Known hypersensitivity to furosemide or documented cross-allergy to sulfonamides.
• State of extreme volume depletion or severe dehydration.
• Active hepatic encephalopathy (diuretic-induced hypokalemia exacerbates cerebral ammonemia).

Relative Contraindications

• Severe baseline hypokalemia (K⁺ < 3.0 mEq/L).
• Gout or severe clinical hyperuricemia (loop diuretics compete for the organic anion transporter, secondary accumulating uric acid in the blood).

Adverse Effects and Toxicity

• Profound hypokalemia and hyponatremia: Requires frequent electrolyte monitoring.
• Hypokalemic Hypochloremic Metabolic Alkalosis: Due to the preferential loss of hydrogen and chloride ions coupled to forced natriuresis of the distal nephron.
• Ototoxicity (Class Critical RAM): The NKCC transporter is also expressed in the stria vascularis of the cochlea in the inner ear (isophorin NKCC1), where it regulates the composition of the endolymph. Rapid administration of high doses of furosemide may cause tinnitus, transient deafness, or permanent hearing loss:

Critical Toxicity: Prevention of Ototoxicity in Intravenous Infusion

Rapid intravenous infusion of furosemide (direct bolus of doses greater than 120-240 mg) saturates cochlear transporters, causing edema in the stria vascularis and sudden sensorineural hearing loss. To minimize this class complication, the following guideline should be applied:

Dose of Furosemide EV Maximum recommended infusion rate: 4 mg/minute

In patients who require high cumulative doses in the acute phase, it is recommended to prefer controlled continuous infusion after an initial bolus, reducing the risk of deleterious plasma peaks in the inner ear.

Relevant Drug Interactions

• Aminoglycoside Antibiotics (Amikacin, Gentamicin): Severe ototoxic and nephrotoxic synergism. Concomitant use should be avoided if possible.
• NSAIDs: They inhibit vasodilatory renal prostaglandins, decreasing secretion and notably attenuating the diuretic effect of furosemide.
• Digoxin: Hypokalemia and hypomagnesemia induced by furosemide critically enhance the affinity of digoxin for the ATPase pump, triggering arrhythmias due to digitalis poisoning.